AusCann has submitted stage one of an application to the Australian Pesticides and Veterinary Medicines Association (APVMA) to supply DermaCann, its cannabinoid-based skincare product for dogs, via prescription through Australian veterinarians.
There are approximately one million dogs in Australia suffering from dermatological conditions, and the global canine skin and dermatitis market is worth an estimated US$1.5 billion.
The move compliments a previously announced submission for approval in South Africa and commercialisation plans for the US, where legislation in certain states permits the sale of animal health products containing CBD without registration.
AusCann CEO Layton Mills said: “Commencing the formal registration pathway with APVMA is consistent with AusCann’s objective of bringing safe, clinically developed and tested medicines for human and animal health to meet patients’ unmet health needs.
“We look forward to bringing this world-first product to veterinarians in Australia and other global markets.”
AusCann announced the acquisition of animal health company CannPal late last year.